GAITHERSBURG, Md. — August 6, 2025 — Leads & Copy — Emergent BioSolutions Inc. (NYSE: EBS) announced its financial results for the second quarter ended June 30, 2025, reporting total revenues of $140.9 million, which exceeded Q2 guidance by $21 million. The company posted a net loss of $12.0 million, an improvement of 96% year-over-year, and an adjusted EBITDA of $28.5 million, a 382% increase compared to the prior year.
According to Joe Papa, president and CEO of Emergent, the company is raising the low end/midpoint of its full-year 2025 profitability guidance due to the strong Q2 performance and the execution of its multi-year transformation plan. Emergent has secured seven biodefense contract modifications this year and continues to assess strategic opportunities for long-term growth.
The company has updated its full-year 2025 financial forecast, projecting total revenues between $765 million and $835 million. Net income is expected to be in the range of $40 million to $65 million, with adjusted EBITDA between $175 million and $200 million. Adjusted gross margin is forecasted at 50% to 52%.
Emergent BioSolutions Inc. is focused on providing life-saving solutions for health threats. The company delivers protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies.
Investor Contact:
Rich Lindahl
Executive Vice President, Chief Financial Officer
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
Source: Emergent BioSolutions Inc.
Source: Emergent BioSolutions Inc.
